The Safety and Intraocular Pressure–Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1

Whitson, Jess T.; Ochsner, Katherine I.; Moster, Marlene R.; Sullivan, Emily; Andrew, Russell; Silver, Lester; Wells, David T.; James, John E.; Bosworth, Charles F.; Dickerson, Jaime E.; Landry, Theresa; Bergamini, Michael V.W.

doi:10.1016/j.ophtha.2006.03.025

Cited by 35 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BAK-free formulations have been demonstrated to be noninferior in reducing IOP as the same medications preserved with BAK [73,[81][82][83][84][85][86][87]. Currently, several BAK-free preserved and preservative-free formulations of ocular hypotensive monotherapies and fixed-dose combinations (e.g., tafluprost, travoprost, bimatoprost, brimonidine, timolol, fixed-combination travoprost/timolol, fixed-combination dorzolamide/timolol) are commercially available.…”

Section: Exposure To Preservativesmentioning

confidence: 99%

Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

Holló

Topouzis

Fechtner

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Compared with non-fixed combinations, fixed-combination glaucoma therapies provide various demonstrated benefits (similar IOP-lowering efficacy with reduced exposure to preservatives and risk of preservative-related ocular surface disease symptoms, elimination of washout associated with insufficient time separation of instillations and reduced number of total instillations). Further, due to simplification of the instillation regimen, fixed combinations may improve treatment adherence and persistence, thereby improving stability of IOP control over time.

show abstract

Section: Exposure To Preservativesmentioning

confidence: 99%

Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

Holló

Topouzis

Fechtner

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…The above mentioned formulations: emulsion, suspension, and ointment are known to cause ocular adverse effects such as irritation, redness of eye and interference with vision. Also, chronic administration may increase systemic API availability which may lead to severe systemic complications [38–40] . Formulations with preservatives also induce adverse reactions upon systemic absorption [41,42] .…”

Section: Conventional Ocular Drug Delivery Systemsmentioning

confidence: 99%

Ocular drug delivery systems: An overview

Patel

Cholkar

Agrahari

et al. 2013

WJP

703

552

View full text Add to dashboard Cite

The major challenge faced by today’s pharmacologist and formulation scientist is ocular drug delivery. Topical eye drop is the most convenient and patient compliant route of drug administration, especially for the treatment of anterior segment diseases. Delivery of drugs to the targeted ocular tissues is restricted by various precorneal, dynamic and static ocular barriers. Also, therapeutic drug levels are not maintained for longer duration in target tissues. In the past two decades, ocular drug delivery research acceleratedly advanced towards developing a novel, safe and patient compliant formulation and drug delivery devices/techniques, which may surpass these barriers and maintain drug levels in tissues. Anterior segment drug delivery advances are witnessed by modulation of conventional topical solutions with permeation and viscosity enhancers. Also, it includes development of conventional topical formulations such as suspensions, emulsions and ointments. Various nanoformulations have also been introduced for anterior segment ocular drug delivery. On the other hand, for posterior ocular delivery, research has been immensely focused towards development of drug releasing devices and nanoformulations for treating chronic vitreoretinal diseases. These novel devices and/or formulations may help to surpass ocular barriers and associated side effects with conventional topical drops. Also, these novel devices and/or formulations are easy to formulate, no/negligibly irritating, possess high precorneal residence time, sustain the drug release, and enhance ocular bioavailability of therapeutics. An update of current research advancement in ocular drug delivery necessitates and helps drug delivery scientists to modulate their think process and develop novel and safe drug delivery strategies. Current review intends to summarize the existing conventional formulations for ocular delivery and their advancements followed by current nanotechnology based formulation developments. Also, recent developments with other ocular drug delivery strategies employing in situ gels, implants, contact lens and microneedles have been discussed.

show abstract

“…Поликвартениум-1 -это соедине-ние четвертичного аммония, и на моделях крыс in vivo было по-казано, что он менее токсичен, чем БАХ. 55 PQ-1 использовался в качестве консерванта в бримонидине, однако только в экспери-менте, 56 и в настоящее время PQ-1 не входит в состав доступных на рынке противоглаукомных препаратов.…”

Section: альтернативы бензалкония хлоридуunclassified

“…66 Кроме того, не было выявлено отличий в эффективности и безопасности глазных ка-пель бримонидина, содержащих в качестве консерванта Пурит и PQ-1. 56 …”

Section: эффективность и переносимость капель не со-держащих бензалкunclassified

Лечение Глаукомы Препаратами, Не Содержащими Консервантов, Является Важной И Реалистичной Целью Будущего

Хоупс¹,

Бродвэй²

2010

European Ophthalmic Review

View full text Add to dashboard Cite

Медикаментозная терапия обычно является методом первого выбора в лечении глаукомы. Однако нежелательные эффекты офтальмологических препаратов потенциально угрожают безопасности и эффективности лечения. Глазные капли во флако- нах содержат множество компонентов, каждый из которых способен вызвать нежелательные реакции, хотя основной причи- ной их возникновения являются консерванты. Влияние консервантов на ткани глаза интенсивно исследовалось как с участием животных, так и человека. Бензалкония хлорид (БАХ) – это высокоэффективный и наиболее часто используемый консервант в препаратах для лечения глаукомы. Тем не менее, БАХ оказывает токсическое воздействие на ткани глаза и потенциально спо- собен вызывать нежелательные эффекты. Применение менее токсичных консервантов или препаратов без консервантов спо- собно улучшить терапию глаукомы.

show abstract

The Safety and Intraocular Pressure–Lowering Efficacy of Brimonidine Tartrate 0.15% Preserved with Polyquaternium-1

Cited by 35 publications

References 5 publications

Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

Ocular drug delivery systems: An overview

Лечение Глаукомы Препаратами, Не Содержащими Консервантов, Является Важной И Реалистичной Целью Будущего

Contact Info

Product

Resources

About